secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001193805-23-001054
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic Q2 2023 net loss $24.0M; cash $77.3M funds into Q4 2024
---------------------------------------------------------------

- Net loss of $24.0M ($0.54/share) vs $21.9M ($0.72/share) in Q2 2022.
- Cash, cash equivalents and investments at $77.3M as of June 30, 2023.
- R&D expenses $21.2M, up from $16.5M YoY, driven by MS and IMU-856 programs.
- Interim CALLIPER trial data in progressive MS expected fall 2023; ENSURE top-line late 2024.
- Positive Phase 1b IMU-856 data in celiac disease; Phase 2 in active celiac being prepared.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380523001054/0001193805-23-001054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380523001054/e618816_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-23-001054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer